AbbVie Nabs Exclusive Worldwide Option for Alpine’s CD28/ICOS Dual Inhibitor
By Ruchi Jhonsa, Ph.D. On June 18th, Seattle-based Alpine Immune Sciences announced that it has made a global option and license deal with AbbVie for the development and commercialization of its …
Read More